Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced additional 48-week results from its global Phase IIb AURA-LV (AURA) study in lupus nephritis (LN) during the National …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced that it has signed a Definitive Agreement granting Merck Animal Health, known as MSD Animal Health outside of …
Cantor analyst Elemer Piros initiates coverage on shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), with an Overweight rating and $14 price target, sending shares rising 4.5% in …
In a research report released Friday, FBR analyst Vernon Bernardino reiterated an Outperform rating on shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) with a …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the outcome of discussions with both the European Medicines Agency (EMA) and the Pharmaceutical and Medical Devices Agency …
Recently, two of the biotech world’s biggest needle movers, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and Pulmatrix Inc (NASDAQ:PULM), have certainly made investors dizzy with …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced the 48-week results from the “Aurinia Early Urinary Protein Reduction Predicts Response Study” (AURION) open-label study of voclosporin …
FBR analyst Vernon Bernardino, one of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) biggest bulls, is out today with a research note on AUPH, after the drug …
After a massive run-up, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are falling over 25% in pre-market trading, after the drug maker announced the pricing of …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are surging 18% today following fourth-quarter and full year 2016 financial results released Thursday evening that have since …
